A new report from bank Barclays (LSE:BARC,NYSE:BCS) projects that the US marijuana market would have a value of US$28 billion if it was legal today, with the potential to grow to US$41 billion on a pre-tax basis by 2028.
Barclays analysts shared a note with investors on Wednesday (May 1), indicating a positive outlook for the next few years in the US marijuana space.
According to a report from CNBC, the bank’s research shows the market could be worth approximately US$41 billion if the drug is fully legalized in the country, with US$28 billion generated for tax revenues.
“While no bonds backed by cannabis tax revenues have been placed thus far, if federal approval is granted, the cannabis muni bond market will likely flourish, amounting to billions if not tens of billions of dollars, in our view,” Barclays said in its note.
The marijuana industry in the US has flourished despite the continued federal illegality of the drug, since several states have moved forward with legal programs.
These state programs vary in availability and allowance of medical and recreational uses to consumers.
As such, publicly traded marijuana firms operating assets scattered across legal states have captured the attention of investors looking for potential gains in the larger US market, compared to the smaller Canadian one.
In October 2018, Canada legalized cannabis for recreational use and launched its open market, with provinces overseeing retail and online sales.
Marijuana investors can also access the US multi-state operator (MSO) market through two new exchange-traded funds on the Toronto-based NEO Exchange, which offers a pool of stocks to invest in. One of the funds is actively managed and closely monitors the space.
Reacting to the agreement between Canopy Growth (NYSE:CGC,TSX:WEED) and MSO Acreage Holdings (CSE:ACGR.U,OTCQX:ACRGF), Troy Dayton, CEO of Arcview Investor Group, told the audience at a recent event that he sees this deal as potentially adding pressure for the US government to move along legalization efforts.
Canopy purchased an option to acquire the MSO in a deal overall worth US$3.4 billion that will become active only once cannabis becomes legal at a federal level.
Canopy can therefore retain its senior listings in Toronto and New York, since the company won’t have any direct involvement with operations that touch the plant in the US.
Kris Krane, president of MSO 4Front Holdings, told the Investing News Network that the potential use of the deal structure by other established non-cannabis firms could open a new communication channel with elected officials.
“Some of these companies spend a lot of money on federal lobbying, and all of a sudden we got a reach in Congress and a reach among federal elected officials that we wouldn’t have had just as an industry alone without the participation of these more established players,” Krane said.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Acreage Holdings is a client of the Investing News Network. This article is not paid-for content.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).